Creative Medical Technology Holdings, INC 8-K filings

Creative Medical Technology Holdings' stockholders approved the full exercise of warrants for 2.79 million common shares at a recent Special Meeting.

Creative Medical Technology Holdings, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all director nominees were elected, executive compensation was approved, and Haynie & Company was ratified as independent accountants.

Creative Medical Technology Holdings, Inc. announced its Compensation Committee approved bonuses for its CEO and CFO totaling $125,000.

Creative Medical Technology Holdings, Inc. raised approximately $4.2 million by inducing existing warrant holders to exercise their warrants, issuing new warrants as an incentive.

Creative Medical Technology Holdings' stockholders approved the full exercise of warrants to purchase 1,799,774 shares of common stock at a special meeting held on May 5, 2025.

Creative Medical Technology Holdings received a letter from Nasdaq regarding a delay in adopting and disclosing its Clawback Policy, but Nasdaq has since confirmed the company is now in compliance and the matter is closed.

Creative Medical Technology Holdings' Compensation Committee approved bonus payments of $70,000 and $30,000 to the CEO and CFO, respectively, on March 10, 2025.

Creative Medical Technology Holdings incentivizes warrant holders to exercise existing warrants through the issuance of new inducement warrants, aiming to raise approximately $3.7 million for working capital.

Creative Medical Technology Holdings has increased its authorized common stock shares from 5 million to 25 million and removed designations for Series A and B preferred stock.

Creative Medical Technology Holdings has finalized a $1.85 million registered direct offering, priced at-the-market, alongside a concurrent private placement of warrants.

Creative Medical Technology Holdings held its 2024 Annual Meeting, electing all director nominees and approving executive compensation and the appointment of Haynie & Company as independent auditors.

Creative Medical Technology Holdings issued a single share of Series B Preferred Stock to its CEO, granting him significant voting power on a proposal to increase the company's authorized common stock shares.